Skip to main content
LigaChem Biosciences Inc. logo

LigaChem Biosciences Inc. — Investor Relations & Filings

Ticker · 141080 ISIN · KR7141080002 KO Professional, scientific and technical activities
Open in API
Filings indexed 295 across all filing types
Latest filing 2020-11-02 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 141080

About LigaChem Biosciences Inc.

https://ligachembio.com/

LigaChem Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the research and development of innovative medicines. Leveraging its core expertise in medicinal chemistry, the company focuses on developing Antibody-Drug Conjugates (ADCs), immuno-oncology drugs, and small molecules. A key asset is its proprietary, next-generation ADC platform technology, engineered to overcome the limitations of conventional ADC technologies. The company's pipeline includes multiple programs targeting oncology, as well as other therapeutic areas such as antibiotics and anti-fibrotics. LigaChem Biosciences actively pursues global drug development through strategic partnerships, including co-development and licensing agreements with international pharmaceutical companies.

Recent filings

Filing Released Lang Actions
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees, including the number of shares, exercise price, and valuation methodology. This type of disclosure regarding capital structure changes and equity-based compensation falls under the category of 'Share Issue/Capital Change' (SHA) within the provided classification schema.
2020-11-02 Korean
투자판단관련주요경영사항
M&A Activity Classification · 100% confidence The document is a regulatory filing from LegoChem Biosciences regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing a technology transfer agreement (licensing deal) for an ADC anti-cancer drug candidate with CStone Pharmaceuticals. This type of disclosure regarding material business agreements, licensing, or strategic partnerships is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or capital raising.
2020-10-29 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details the change in share ownership by Quad Investment Management Corp. in LegoChem Biosciences. Since this is a specific regulatory disclosure regarding significant shareholding thresholds, it falls under the 'Major Shareholding Notification' category.
2020-10-07 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the number of shares, exercise price, and the board's resolution date. This type of disclosure regarding capital structure changes and employee incentive schemes is classified as a regulatory filing under the RNS category as it does not fit into specific categories like director dealings or share repurchases.
2020-09-10 Korean
반기보고서 (2020.06)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Semi-Annual Report' (반기보고서) for LegoChem Biosciences, covering the period from January 1, 2020, to June 30, 2020. It contains detailed corporate information, capital changes, shareholding structure, and financial governance details, which are characteristic of an interim financial report. In the context of Korean regulatory filings (DART), this is a standard 'Interim/Quarterly Report'. H1 2020
2020-08-13 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing submitted to the Financial Services Commission/Korea Exchange regarding the granting of stock options (주식매수선택권 부여). It details the number of shares, exercise price, grant date, and the board's resolution. Since this is a specific regulatory disclosure regarding share-based compensation and capital structure changes that does not fit into the other specific categories like 'Director's Dealing' or 'Share Issue', it is classified as a Regulatory Filing (RNS).
2020-08-03 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.